arrow
M

Massimo Degan

centro di riferimento oncologico di aviano (cro)
H指数:32
被引数:3,600

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia

免疫球蛋白同种型内多样化测量的结果细化了慢性淋巴细胞白血病中IGHV突变状态的临床影响。

Leukemia
IF13.4
2025-06-180
OAAI
Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

V-Rbac背景下微小残留病评估,一项Fondazione Italiana Linfomi (FIL)风险定制II期临床试验

BLOOD
IF23.1
2024-11-050
PRE
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience
2024-07-151
OAAI
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
LEUKEMIA
IF13.4
2023-02-1813
OAAI
Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network
2021-10-011
OAAI
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma

免疫球蛋白kappa缺失元件重排是套细胞淋巴瘤最小残留疾病评估的候选靶标

2020-08-282
PREAI
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia
2019-10-0317
OAAI
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network

非霍奇金淋巴瘤的最小残留疾病 (MRD): FIL (Fondazione Italiana Linfomi) MRD网络中疾病水平极低的骨髓样本的实验室间重现性

2019-08-1612
PREAI
Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia
2017-07-279
OAAI
Mutations in the 3′ untranslated region of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia
2017-05-2619
OAAI
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
2013-11-0518
OAAI
Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
2010-01-1444
OAAI
CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival
2009-04-30148
OAAI